ARTICLE | Clinical News
CSL112: Phase I data
December 3, 2012 8:00 AM UTC
A double-blind, placebo-controlled, Australian Phase I trial in 57 healthy volunteers showed that single ascending-doses of 5-135 mg/kg CSL112 caused dose-proportional elevation from baseline in APOA1...